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Cancer and antibiotic resistance are two global health threats that usually hamper clinical chemother-
apeutic efficacy. Particularly for lung cancer, bacterial infections frequently arise thereby complicating
the course of cancer treatment. In this sense, three new neutral luminescent cycloplatinated(II) photo-
sensitizers of the type [Pt(dmba)(L)] (dmba ¼ N,N-dimethylbenzylamine-kN,kC; L ¼ 2-(benzo[d]oxazol-
2-yl)-phenolato-kN,kO 1, 2-(benzo[d]thiazol-2-yl)-phenolato-kN,kO 2, and 2-(1-methyl-1H-benzo[d]
imidazole-2-yl)phenolato-kN,kO 3) have been characterized and developed to potentially eliminate both
resistant bacteria and lung cancer cells. The phototherapeutic effects of complex 2 have been evaluated
using low doses of blue light irradiation. Complex 2 exerted promising photoactivity against pathogenic
Gram-positive bacteria strains of clinical interest, displaying a phototoxic index (PI) of 15 for methicillin-
resistant Staphylococcus aureus, one of the major microorganisms predominating lung infections. Like-
wise, the anticancer activity of 2 was also increased upon light irradiation in human lung A549 cancer
cells (PI ¼ 36). Further in vitro experiments with this platinum(II) complex suggest that ROS-generating
photodynamic reactions were involved upon light irradiation, thus providing a reasonable mechanism
for its dual anticancer and antibacterial activities.
© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the common challenges faced by chemotherapy patients
are bacterial infections usually caused by one type of microor-
ganism or by more than one type (polymicrobial infections) due to
inherent cancer immunodeficiencies, neutropenia, disruption of
mucosal barriers, etc. [1e3]. During the last decades, Gram-positive
bacterial infections including those caused by multidrug-resistant
(MDR) bacteria such as methicillin-resistant Staphylococcus aureus
or vancomycin-resistant Enterococcus species predominate over
Gram-negative bacterial infections [3e6].(C. Janiak), nbusto@ubu.es
uiz).
er Masson SAS. This is an open acceTherefore, antibiotics are often prescribed during chemotherapy
treatment of cancer disease [7e12]. Regarding the latter, in spite of
the success of cisplatin (CDDP), carboplatin, and oxaliplatin in
therapy for various solid cancers, problems such as drug-resistance
and serious side effects hampered their clinical applications and
efficacy [13]. As CDDP exerts anticancer activity via DNA lesions
[14], it is important to develop new non-conventional anticancer
drugs. Metal complexes provide some unique opportunities
compared to organic compounds, having access to modes of action
that are not possible with purely organic compounds [15].
Currently, organometallic complexes with intermediate properties
between the classical inorganic and organic molecules have
recently been considered as promising alternatives not only for
cancer therapy but also as antimicrobials because of the high
reactivity provided by the three dimensional shape of metal com-
plexes and because the coordination ligands in such complexes can
be modulated for their pharmacological properties [16e18]. In
particular, C^N ligands offer higher stability of the metal complexesss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Chart 1. Structures of A) pro-ligands HL and B) new platinum(II) complexes used in this work.
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improving their lipophilicity and cellular uptake [16,19e27]. Het-
erocyclic compounds play essential roles in life and biochemical
processes [12,28]. In this sense, the exploitation of possible syner-
gistic effects of the pharmacologically widely used benzimidazole
and benzothiazole scaffolds [29e31] with inherent bioactivity and
the potential affinity of bioactive metal organometallic complexes
[32] is of great interest. Moreover, the behavior of platinum is quite
unknown in the field of microbiology and only a few studies of
metal complexes have focused on its antibacterial applications [33].
In a recent work Frei et al. report the evaluation of metal-containing
compounds for antimicrobial activity, among them, five Pt com-
plexes testedwere active against methicillin resistant S. aureus [33].
On the other hand, light is an outstanding external stimulus of
anticancer drugs due to its non-invasive nature and a high level of
location and timing control, generating less systemic toxicity for
cancer patients and being more effective against resistant cancers
[34,35]. The photoactivation could occur either via a bond photo-
cleavage reaction (i.e., photoactivated chemotherapy (PACT))
[36e40] or by photodynamic therapy (PDT), the latter involving
formation of reactive oxygen species (ROS) through the sensitiza-
tion of oxygen [41e48]. The octahedral Ru(II) polypyridyl complex
(TLD1433) already entered clinical trials as invasive bladder cancer
PDT a light-irradiated photosensitizer [46], and a square-planar
Pd(II) bacteriopheophorbide (the so-called padeliporfin or WST
11) has been approved for PDT of prostate cancer [49]. An Ir(III)-
coumarin derivative able to act as a potent PDT agent against
prostate differentiated and tumorigenic cancer stem cells has been
recently reported [50]. Similarly, photodynamic microorganism
inactivation (PDI) is an interesting strategy that is increasingly used
both as therapeutic and as prophylactic modalities for the eradi-
cation of MDR bacteria strains [51,52]. It is noteworthy that the
photophysical and anticancer properties of some metal complexes
bearing benzazolate ligands, and in particular their potential as PDT
agents has been recently reported [44,53].
In this context, the development of new compounds provided
with antibacterial and antitumor activities that can be easily
modulated by photoactivation could be an interesting approach in
combating bacterial infections in cancer chemotherapy patients.
Herein, we describe the synthesis of three luminescent plati-
num(II) complexes of the type [Pt(C^N)(L)] (Chart 1), where the
deprotonated N,N-dimethylbenzylamine-kN, kC ligand (dmba)
remains as the C^N backbone and the chromophoric 2-
benzoazole-phenolato N^O ligand has been varied to evaluate2
the effect on their antibacterial and anticancer activities along
with their photopotentiation.
2. Results and discussion
2.1. Synthesis of the new Platinum(II) complexes
A series of neutral cycloplatinated(II) complexes of the type
[Pt(dmba)(L)] (Chart 1) containg chromophoric 2-benzoazole-
phenolato N^O ligands were prepared from [Pt(dmba)(DMSO)Cl] in
moderate to good yields (dmba ¼ N,N-dimethylbenzylamine-
kN,kC; HL1 ¼ 2-(20-hydroxyphenyl)benzoxazole, HL2 ¼ 2-(20-
hydroxyphenyl)benzothiazole, HL3 ¼ 1-methyl-2-(20-hydrox-
yphenyl)benzimidazole). Complexes 1e3 gave satisfactory
elemental analyses and were also characterized by positive-ion ESI-
MS 1H, 13C and 195Pt NMR (including COSY, HSQC and HMQC) and
UV/Vis spectroscopy (Figs. S1e28). The 1H NMR spectrum of com-
plex 2 in DMSO‑d6 show that both the N-methyl groups and the
methylene protons of the dmba are diastereotopic, two separate
singlets being observed for the former and two AB doublets for the
later (Fig. S8). Therefore, there is no plane of symmetry in the metal
coordination plane [21,54]. Furthermore, the aromatic signal of
dmba at d 6.3 ppm is flanked by 195Pt satellites (observed as
shoulders). Complex 1 showed broad resonances at 25 C that
sharpens at 75 C in a reversibly manner (Fig. S22), whereas com-
plex 3 was reactive in DMSO‑d6 even within 10 min at room tem-
perature (Fig. S25). Therefore, NMR characterization of complex 3
was performed in CD2Cl2 (195Pt satellites clearly being observed as
shoulders) and in DMF-d7, being stable in this solvent in the
absence of light at least for 72 h (Fig. S24). 1He1H NOESY spectrum
of 3 in CD2Cl2 showed a NOE cross-peak between the aromatic H8
and the NMe groups of the dmba (Fig. S19), indicating that for 3, in
solution, the nitrogen of the imidazole ligand is coordinated trans
to C of the dmba (Fig. 1B). However, the same experiment for 1 and
2 in DMSO‑d6 showed NOE cross-peak between H8 and the aro-
matic H9 of the dmba (Figs. S5 and S12, respectively). The positive-
ion ESI mass spectra of the new complexes exhibited the [M þ H]þ
signals with the expected isotopic distribution pattern
(Figs. S26eS28).
2.2. Crystal structures by X-ray diffraction
Single crystals for X-ray diffraction analysis were obtained for 1
by standing in DMSO‑d6 solution over 3 days, whereas those of 2
Fig. 1. Molecular structures with atom numbering schemes for (A) 1, (B) 2, and (C) 3,CH2Cl2 (CH2Cl2 omitted for clarity). Thermal ellipsoids of non-hydrogen atoms are drawn at the
50% probability level. Selected bond lengths and angles for 1e3 are shown in the Supporting Information.
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their corresponding saturated solution in CH2Cl2/toluene. The
structures of 1e3 are shown in Fig. 1. In all cases the Pt atom has a
distorted square planar environment, with the CePteN bite angle
deviating from 90 due to the bite of the cyclometallated ligand.
The PtCC^N bond distances lie within the expected range, that is,
very close to 2.0 Å [21,23]. Two symmetry-independent molecules
of 2 were found here in the structural asymmetric unit. A note-
worthy and striking difference in the three molecular structures is
the cis/trans-positioning of the phenolato group or the N atom of
the oxazolyl, thiazolyl or imidazolyl ring relative to the benzyl-
amine ligand (Chart 1). In 1 and 2 the phenolato O atom is trans to
the ortho-metallated carbon atom, the N atom of the oxazolyl and
thiazolyl is trans to the amine group (Fig. 1A and B). Whereas in
3,CH2Cl2 the phenolato O atom is trans to the amine group and the
N atom of the imidazolyl is trans to the ortho-metallated carbon
atom (Fig. 1C). The supramolecular packing interactions have been
analyzedwith PLATON [55]. The packing in 1 is organizedmainly by
p- p interactions (Fig. S29), whereas the structures of 2 and
3,CH2Cl2 are dominated by CeH$$$p interactions [56e61]
(Figs. S30eS32, respectively and Tables S7eS9) [62]. There are no p
- p interactions in 3$CH2Cl2.2.3. Photophysical and photochemical properties
Absorption and emission spectra of the complexes in aqueous
buffered solution at pH ¼ 7.0 are shown in Fig. S33. In general, the3
absorption spectra of benzazolate complexes are characterized by
intraligand transitions (IL). The band at the shorter wavelength is
mainly assigned to the pep* transition of the benzazolate aromatic
system [63], and the bands at longer wavelength are attributed to IL
transition associated with a charge transfer (CT) from lone pairs of
phenolate (donor) to the heterocycle (acceptor). The energy cor-
responding to this intraligand charge transfer (ILCT) band depends
on the metal, its oxidation state and the ligands present in the
molecule [64]. As observed the differences in absorption spectra
between compounds 1/2 and complex 3 are notably, no absorption
being observed above 450 nm for 3. Bands at l > 380 nm observed
for 1 and 2 could be attributed to spin-allowed metal to ligand
(1MLCT, dp(Pt)/p* [65]. Upon excitation at 375 nm,1 and 2 showa
structured band of emission in the green to orange region centered
at 545 and 615 nm, respectively (Fig. S33), and are therefore slightly
shifted to longer wavelengths with respect to the free benzazoles
(480 and 510 nm for HL1 and HL2, respectively). The emission
lifetimes of complexes 1 and 2 are 650 and 970 ns, respectively, in
aqueous buffered solution at pH ¼ 7.0, indicating that both com-
plexes are phosphorescent. Complex 3 has a much shorter lifetime
(3 ns in aqueous solution), whichmay be due to the absence ofp -p
interactions (see above for the crystal structure discussion) due to
the NMe substituent. Their emission lifetimes in DMF were much
smaller (Table S11). The absorption spectrum of the three com-
plexes in DMF solution at 25 C (Fig. S34) presented no significant
changes over 24 h. However, the UVevis measurements showed
that 3 was not stable in DMSO after 10 min (Fig. S35), as we have
Table 1
MIC values of the studied compounds in the dark and upon 40 min of blue light
irradiation (420 nm, 6 J cm2)a.
E. faecium S. aureus
Dark Irradiated Dark Irradiated
1 >100 >100 >100 >100
2 5 2 30 2
3 75 75 75 75
a Except for E. faecium, tirr ¼ 2 h
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observed for 1 and 2 in the same conditions. On the other hand, a
big decrease in the intensity of the UVevis bands was observed for
1 and 3 in aqueous buffered solution containing sodium cacodylate
over time (Fig. S36).2.4. Antibacterial activity
The antibacterial activity of the compounds under study was
screened in pathogenic bacteria belonging to the ESKAPE group
with a high rate of antibiotic resistance (Table 1 and Table S12). Two
Gram-positive (vancomycin-resistant Enterococcus faecium and a
methicillin-resistant Staphylococcus aureus) and two Gram-
negative (Acinetobacter baumanii and Pseudomonas aeruginosa)
were employed. The activities of the compounds were expressed as
minimal inhibitory concentration (MIC) values i.e., the lowest
concentration of the compound that prevents bacterial growth.
None of the compounds were active against Gram negative bacteria
(MIC values > 100) (Table S12). By contrast, complex 2was themost
active compound against Gram positive strains, thus indicating that
the benzothiazole ligand seems crucial for the antibacterial activity,
both in the dark and after blue light irradiation. The sulfur atom
makes the complex a very potent antimicrobial agent with a
remarkable photoactivation in S. aureus strain where the photo-
index value (PI¼MICirr/MICdark) is 15 after short irradiation periods
(Table 1). Thus, 2 can be considered a new promising compound to
treat bacterial infections by photodynamic inactivation (PDI).2.5. Antiproliferative activity and phototoxicity
The antiproliferative activities of platinum complexes were then
investigated against a panel of cancer cell lines including lung
(A549), colon (SW480) and ovarian (A2780 and A2780cis) cancer
cells as well as an in non-tumorigenic ovarian (CHO cells); cisplatin
being used as control. None of the ligands were found to be cyto-
toxic whereas all the studied compounds showed remarkable
cytotoxicity against tested tumor cells with half-maximumTable 2
IC50 (mM) values obtained for Pt(II) compounds after 1 h incubation, 1 h irradiation wit
provided.a
Compound A549
1 Dark 57 ± 4
Irradiated 2.2 ± 0.1
2 Dark 25 ± 3
Irradiated 0.69 ± 0.03
3 Dark 37 ± 6
Irradiated 22 ± 4
a Data expressed as mean values ± SD of three independent experiments (n ¼ 4).
b A549 were pretreated with 5 mM of N-acetyl-cysteine (NAC) for 1 h prior treatmen
c PI ¼ [IC50]dark/[IC50]irr for A549 cells.
4
inhibitory concentration (IC50) values in the low micromolar range
(Table S13). The cytotoxicity of the complexes was confirmed in
A549 cells bymicroscopy after 24 h of incubation in the presence of
the Pt(II) complexes at the IC50 values and 2-fold the IC50 values
(Fig. S37). Moreover, the platinum compounds were able to over-
come cisplatin resistance in A2780cis cell line.
In addition, phototoxicity was evaluated in lung carcinoma
A549 cells. First, cell viability was checked after application of
visible light alone without complexes, finding that it was not
affected (Fig. S38). Low dark toxicity was found in both cancer
(A549) and normal (CHO) cells (IC50 between 25 and 59) for 1 and 2
(Table 2). However, blue light irradiation on the cellular culture
triggered phototoxicity of these compounds as their IC50 values
significantly decreased, thus rendering phototoxic indices (PI) up to
26 and 36 for 1 and 2, respectively (Table 2). Such photo-
potentiation was not observed for 3, probably due to low absorp-
tion of light in this region.
To investigate possible photocleavage effects, a series of exper-
iments applying blue light irradiation to both DMF and cell
medium-diluted (DMEM) solutions of the Pt compounds prior
treatment was conducted. No differences in IC50 between treat-
ments with irradiated and non-irradiated solutions were observed
for DMF solutions (Table S14). On the contrary, the IC50 values
increased when the complexes were pre-irradiated in DMEM. This
indicates that species less cytotoxic than 1e3 are generated as a
consequence of irradiation and, subsequently, that a mechanism
such as PACT should be ruled out. However, when 1 and 2 com-
plexes were irradiated with bacteria or cells, in cell medium, a
strong increase in cytotoxicity (Tables 1 and 2) was observed, which
indicates that these complexes are more active upon irradiation
and photostable inside the cells. This led us to conclude that a PDT
mechanism would be responsible for the high phototoxic indices
(PI) observed.
Overall, the results suggest that sulfur-containing benzothiazole
ligand seems to improve the phototherapeutic selectivity of the
present compounds and, therefore, 2 was selected for further
studies.
2.6. Photo-oxidation of NADH and singlet oxygen quantum yields
In order to shed light on the photopotentiation effects for the
best performer 2, we first observed that after 465 nm blue light
irradiation (18 J cm2), small changes were seen in the UVevis
absorption spectral profile of 2 compared to the sample in the
dark in water/DMF (80:20) solution at ambient temperature
(Fig. S39), which can be easily related to the deactivation mecha-
nism observed for irradiated solutions in cell culture media
(Table S14). Next, we measured its singlet oxygen (1O2) generation
quantumyield (FD) in CH3CN spectroscopically (Fig. S40), obtaining
a value of 0.42, which is close to that of the reference [Ru(bpy)3]Cl2h (465 nm, 12.6 J cm2) and 24 h of cell recovery. Phototoxic indices (PI) are also
A549 (þNAC)b CHO PIc
69 ± 5 37 ± 3
4.2 ± 0.5 26
26 ± 3 59 ± 4
1.8 ± 0.1 36
44 ± 7 13 ± 2
40 ± 4 2
t schedule.
Fig. 2. UVevis spectra for the photocatalytic oxidation of NADH (100 mM) by complex 2 (5 mM) in a mixture of H2OmQ/DMF 90/10 (v/v) at 298 K in the dark or under blue light
irradiation (465 nm, 18 J cm2). The NADH oxidation turnover number (TON) was 3.3 after 30 min.
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photo-oxidation of NADH, an important coenzyme in living cells,
which participates in the maintenance of the intracellular redox
balance in neoplastic tissues [67]. As shown in Fig. 2, complex 2was
photo-catalyst for NADH photo-oxidation as evidenced from the
decrease of absorbance of NADH's characteristic band at 339 nm.
The turnover frequency (TOF) of 2 for NADH photo-oxidation was
6.6 h1.
2.7. Cellular accumulation and localization
The luminescence of 1 and 2 allowed us to evaluate cellular
localization by confocal microscopy. A549 cells treated with plat-
inum complexes for 0.5 and 3 h exhibited mild to strong intracel-
lular luminescence and showed a punctuated pattern around cell
cytoplasm, indicating that compounds were able to rapidly inter-
nalize in living cancer cells (Fig. 3A and Fig. S41). This cytoplasmic
distribution was corroborated through platinum content determi-
nation by ICP-MS (Fig. S42). All the complexes accumulated into
A549 cells in a greater extent than cisplatin after 24 h in the dark.
Particularly, compound 2 exhibited significantly higher uptake in
the non-nuclear fraction compared to 1 and 3 (Fig. 3B).
2.8. Intracellular ROS generation upon light irradiation
Since photo-generation of 1O2 and photo-oxidation catalysis of
NADH were observed for complex 2, we decided to monitor
intracellular ROS levels of 2-treated cancer cells using the fluores-
cent probe dihydroethidium (DHE), which is oxidized in the5
presence of ROS thereby intercalating into DNA and exhibiting red
fluorescence [68]. Compound 2 (10 mM) increased DHE fluores-
cence only upon light irradiation, hence indicating its ability for
ROS production, while irradiation alone did not result in any
observable effects (Fig. 4A and Fig. S43). Moreover, incubation of
A549 cells with the well-known ROS scavenger N-acetyl-cysteine
(NAC; 5 mM) prior to treatment with compounds attenuated their
phototoxic effects, which confirmed that ROS were required for the
compounds to act under light irradiation (Table 2 and Fig. S44).2.9. Morphological changes and apoptosis induction
The ability for 2 to photo-induce cell death prompted us to
check the type of cellular damage induced in A549 cells upon
irradiation. As shown in Fig. 4B and Fig. S44, under dark conditions
2 rapidly induced morphological changes characterized by nuclear
condensation as a reduction in cell size was detected in forward
light scatter (FSC) and concomitant transient increase observed in
the side scatter (SCC). These morphological changes were also
consistent with apoptosis induction, which was further confirmed
by flow cytometry (Fig. S45). In contrast, upon 1 h of blue light
irradiation, 2 led to dramatic changes in the morphology of
A549 cells resulting in an increase of cell size and cell debris that
might be ascribable to oxidative damage (Fig. 4B). Overall, these
results led us to hypothesize that the phototoxicity of 2 was due to
ROS-generating PDT reactions that lead to cellular oxidative
damage.
Fig. 3. A) Confocal microscopy images of A549 cells after 0.5 h treatment with 1 and 2 at 10 mM. Scale bar: 50 mm. B) Relative Pt accumulation in the nuclear and non-nuclear
fraction of A549 cells exposure to complexes 1e3 or cisplatin at 2 mM after 24 h expressed as nanograms of Pt in one million cells.
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In summary, we report some new neutral luminescent cyclo-
platinated(II) 2-benzoazole-phenolato N^O complexes of the type
[Pt(dmba)(L)]. Noteworthy, the 2-(benzothiazolyl)phenolato-N,O
compound 2 photo-generated 1O2, catalyzed photo-oxidation of
NADH and displayed antimicrobial activity against two Gram pos-
itive bacteria strains of clinical interest, showing remarkable pho-
toactivity in methicillin-resistant S. aureus (PI ¼ 15) upon light
irradiation. Complex 2 also exhibited high antiproliferative activity
in vitro against cancer cells and application of low-doses of blue
light (12.6 J cm2) significantly improved the cytotoxicity against
A549 lung carcinoma cells (PI ¼ 36). Additional experiments
confirmed intracellular ROS being produced after light irradiation
with 2 as well as important changes in cell morphology, which6
were consistent with its photocytotoxicity. The dual anticancer and
antibacterial activity of 2 in the presence of light makes it a
promising luminescent platinum PDT candidate for potential
elimination of pathogenic multi-resistant bacterial infections in
lung cancer chemotherapy.4. Materials and methods
4.1. General procedures
Unless otherwise noted, preparations were carried out under
atmospheric conditions. [Pt(dmba)(DMSO)Cl] and 1-methyl-2-(20-
hydroxyphenyl)benzimidazole (HL3) were prepared using reported
procedures [22,69]. HL1, HL2 and all other reagents were obtained
from commercial sources and used without further purification.
Fig. 4. A) Fluorescent detection of ROS in A549 cells after treatment with 2 (10 mM) in the dark or upon irradiation with blue light (l ¼ 465 nm, 1 h). Cells were stained with
dihydroethidium (DHE) at 10 mM. Scale bar: 100 mm. B) FSC-SSC profiles of A549 cells with (red) and without (black) blue light (l ¼ 465 nm, 1 h) in the absence or presence of 2
(10 mM).
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EA 1108 microanalyzer. The 1H, 13C and 195Pt NMR spectra were
recorded on a Bruker AC 300 E or a Bruker AV 400 spectrometer.
Chemical shifts are cited relative to SiMe4 (1H and 13C, external) and
Na2[PtCl6] (195Pt, external). ESI mass analyses were performed on a
HPLC/MS TOF 6220. The isotopic distribution of the heaviest set of
peaks matched very closely that calculated for the formulation of
the complex cation in every case. UV/Vis spectroscopy was carried
out on a PerkinElmer Lambda 750 S spectrometer with operating
software. Fluorescence measurements were carried out with a7
PerkinElmer LS 55 50 Hz Fluorescence Spectrometer and Fluores-
cence Lifetime measurements in a FLS980 equipment (Edinburgh
Instruments) in which the photoexcitation was made with a EPL
375 pulse diode laser and the data emission collected was analyzed
by FAST 3.4.0 software. Confocal microscopy image processing and
display were carried out with ImageJ software.
4.2. Preparation of monomeric Pt(II) compounds 1, 2 and 3
The corresponding 2-benzoazole-phenol HLn (0.23 mmol) was
E. Ortega, C. Perez-Arnaiz, V. Rodríguez et al. European Journal of Medicinal Chemistry 222 (2021) 113600treated with methanolic KOH (5 mL, 25.81 mg, 0.26 mmol) for
15 min. The resulting solution was treated with a suspension of
[Pt(dmba)(DMSO)Cl] (0.1 g, 0.23 mmol) in methanol (15 mL) at
room temperature for 48 h (for complexes 1 and 3) or for 24 h at
65 C (complex 2). After removing solvent under reduced pressure,
the residue was redissolved by the addition of CH2Cl2 (20 mL). The
resulting solution was filtered through Celite, and then the solvent
was evaporated to dryness. The residue was treated with ether to
give a precipitate that was filtered off and air-dried.Complex 1. Intense yellow solid. Isolated yield: 65% 1H NMR
(300 MHz, DMSO‑d6): d 7.82e7.75 (m, 2H, H4þH5), 7.45e7.37 (m,
2H, H6þH7), 7.36e7.26 (m, 2H, H2þH8), 7.02 (dd, 1H, H12, J ¼ 7.2,
J ¼ 0.9 Hz), 6.84 (td, 1H, H11, J ¼ 7.2, J ¼ 1.2 Hz), 6.79e6.76 (m, 2H,
H1þH9), 6.60e6.54 (m, 2H, H3þH10), 4.11 (s, br, 2H, CH2N), 2.83 (s,
br, 6H, N(CH3)2). 13C NMR (75.4 MHz, DMSO‑d6): d 169.2 (Q), 159.0
(Q), 149.2 (Q), 148.9 (Q), 138.5 (Q), 136.0 (CH1 or CH9), 134.6 (CH2 or
CH8), 130.1 (Q), 128.1 (CH4), 126.1 (CH6 or CH7), 124.3 (CH2 or CH8),
123.6 (CH3 or CH10), 123.1 (CH1 or CH9), 122.6 (CH11), 121.1 (CH12),
120.0 (CH6 or CH7), 114.3 (CH3 or CH10), 111.3 (CH5), 111.1 (Q), 74.5
(CH2N), 50.9 (NCH3). 195Pt NMR (128.63MHz, DMSO‑d6): d2896.7.
ESI-MS (pos. ion mode, DMF): m/z ¼ 540.12 [M þ H]þ. Anal. Calcd.
for C22H20N2O2Pt: C, 48.98; H, 3.74; N, 5.19. Found: C, 49.15, H, 3.61;
N, 5.02 (%).Complex 2. Intense orange solid. Isolated yield: 60%. 1H NMR
(400 MHz, DMSO‑d6): d 8.10e8.08 (m, 1H, H5), 8.04e8.02 (m, 1H,
H8), 7.52 (dd, 1H, H4, J ¼ 8.0, J ¼ 1.6 Hz), 7.42e7.27 (m, 2H, H6þH7),
7.25 (ddd, 1H, H2, J ¼ 8.4, J ¼ 6.8, J ¼ 1.6 Hz), 6.96 (d, 1H, H12,
J ¼ 7.2 Hz), 6.79e6.76 (m, 2H, H1þH11), 6.54 (ddd, 1H, H3, J ¼ 8.0,
J ¼ 7.2, J ¼ 1.2 Hz), 6.48 (td, 1H, H10, J ¼ 7.6, J ¼ 1.2 Hz), 6.29 (dd, 1H,
H9, J ¼ 7.6, J ¼ 0.8 Hz), 4.38 (d, 1H, CH2N, J ¼ 13.6 Hz), 3.74 (d, 1H,
CH2N, J ¼ 13.6 Hz, Pt satellites are observed as shoulders). 3.07 (s,
3H, NCH3), 2.56 (s, 3H, NCH3)$13C NMR (75.4 MHz, DMSO‑d6):
d 169.6 (Q), 167.5 (Q), 151.9 (Q), 150.3 (Q), 137.2 (CH9), 135.9 (CH2),
132.7 (Q), 132.4 (Q), 130.6 (CH4), 127.4 (CH6 or CH7), 127.4 (CH6 or
CH7), 126.7 (CH5), 125.1 (CH10), 123.9 (CH1þCH8þCH11), 122.2
(CH12), 116.2 (CH3), 75.8 (CH2N), 52.5 (NCH3), 52.0 (NCH3). 195Pt
NMR (128.63 MHz, DMSO‑d6): d 2967.8. ESI-MS (pos. ion mode,
DMF): m/z ¼ 556.10 [M þ H]þ. Anal. Calcd. for C22H20N2OPtS: C,
47.56; H, 3.63; N, 5.04; S, 5.77. Found: C, 47.65, H, 3.48; N, 4.83; S,
5.88 (%).8
Complex 3. Pale yellow solid. Isolated yield: 56%. 1H NMR
(400 MHz, CD2Cl2): d 7.89e7.87 (m, H8), 7.55e7.51 (m, 2H, H5þH9),
7.46e7.39 (m, 3H, H4þH6þH7), 7.17 (ddd, 1H, H2, J ¼ 8.4, J ¼ 7.2,
J ¼ 1.6 Hz), 7.06e6.97 (m, 3H, H10þH11þH12), 6.92 (dd, 1H, H1,
J ¼ 8.4, J ¼ 1.2 Hz), 6.74 (td, 1H, H3, J ¼ 8.4, J ¼ 1.2 Hz), 3.93 (s, 3H,
NCH3), 3.82 (s, 2H, CH2N, Pt satellites are observed as shoulders),
3.0 (s, 6H, NCH3 dmba, JHPt ¼ 33.6 Hz). 13C NMR (100.82 MHz,
CD2Cl2): d 171.9 (Q), 151.8 (Q), 148.4 (Q), 140.1 (Q), 137.7 (Q), 137.3
(Q), 132.8 (CH2), 131.6 (CH5 or CH9), 129.2 (CH4), 124.4 (CH10 o CH11
or CH12), 123.5 (CH6þCH7þ {CH10 or CH11 or CH12}), 121.5 (CH1),
120.6 (CH10 or CH11 or CH12), 119.1 (Q), 117.2 (CH8), 115.5 (CH3), 111.2
(CH5 or CH9), 77.4 (CH2N), 55.0 (NCH3 dmba), 34.0 (NCH3). 195Pt
NMR (128.63 MHz, CD2Cl2): d 2776.31. ESI-MS (pos. ion mode,
DMF): m/z ¼ 553.16 [M þ H]þ. Anal. Calcd. for C23H23N3OPt: C,
50.00; H, 4.20; N, 7.61. Found: C, 50.08, H, 4.05; N, 7.43 (%).
4.3. X-ray crystal structure analysis
Single crystals for X-ray diffraction analysis were obtained for 1
by standing in DMSO‑d6 solution over 3 days, whereas those of 2
and 3,CH2Cl2 were obtained from the slow diffusion of hexane into
their corresponding saturated solution in CH2Cl2/toluene/hexane
(2:1:3). A summary of crystal data collection and refinement pa-
rameters for all compounds are given in Table S1-S6, in the Sup-
porting Information. Crystals were mounted on glass fibres and
transferred to the cold gas stream of the diffractometer Bruker
Smart APEX. Data were recorded with Mo Ka radiation
(l ¼ 0.71073 Å) in u scan mode. Absorption correction for the
compound was based on multi-scans. The structures were solved
by direct methods (SHELXS-97) [70]; refinement was done by full-
matrix least squares on F2 using the SHELXLE-2014 program [71];
empirical (multi-scan) absorption correctionwith SADABS (Bruker)
[72]. All non-hydrogen positions were refined with anisotropic
temperature factors. Hydrogen atoms for aromatic CH, aliphatic
CH2 and CH3 groups were positioned geometrically (CeH ¼ 0.95 Å
for aromatic CH, CeH ¼ 0.99 Å for CH2, CeH ¼ 0.98 Å for CH3) and
refined using a riding model (AFIX 43 for aromatic CH, AFIX 23 for
CH2, AFIX 137 for CH3), with Uiso(H) ¼ 1.2Ueq(CH, CH2) and
Uiso(H) ¼ 1.5Ueq(CH3). Graphics were drawn with DIAMOND
(Version 4.6.2) [73]. The structural data has been deposited with
the Cambridge Crystallographic Data Center as CCDC numbers
2007158e2007160 for 1e3, respectively.
4.4. Bacterial strains and antibacterial activity
E. faecium CECT 5253 (vancomycin resistant, Gram positive
bacteria) was maintained in Tryptic Soy (TS) broth or agar at 37 C.
S. aureus CECT 5190 (methicillin resistant, Gram positive bacteria),
A. baumannii ATCC 17978 (Gram negative bacteria) and
P. aeruginosa PAO1 (Gram negative bacteria) were mantained at
37 C in Mueller-Hinton (MH) broth or agar while E. faecium. The
antibacterial activity was evaluated by the broth microdilution
plate method according to CLSI criteria against ESKAPE (Enter-
occocus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Aci-
netobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
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prepared in MHB (1:2 dilutions) in 96-well plates, then plates were
inoculated with a final concentration of 5  105 CFU/mL. For pho-
toactivation studies, bacteria were irradiated during 2 h with LED
blue light (420 nm, 6 J cm2), except for S. aureus that was irradi-
ated 40 min. Then, bacteria were incubated at 37 C for 18e20 h.
The reported Minimum Inhibitory concentrations (MIC) are the
mean values from at least two independent experiments with three
replicates.
4.5. Cell lines and culture
Human epithelial lung cancer cell line, A549, and Chinese
Hamster Ovary cell line, CHO, were grown in F-12 cell medium
supplemented with 10% fetal bovine serum (FBS) and 2 mM L-
glutamine. SW480 cells were cultured in DMEM supplemented
with 10% FBS and and 1% amphotericin-penicillin-streptomycin
solution. A2780 and A2780cis cells were grown in RPMI-1640
supplemented with 2 mM Glutamine, 10% FBS and 1%
amphotericin-penicillin-streptomycin solution. Cells were main-
tained in a humidified incubator at 310 K in a 5% CO2 atmosphere
and subcultured twice a week with appropriate density and were
confirmed to be mycoplasma-free using Hoechst DNA staining
method. A2780cis cells were incubated with 1 mMof cisplatin every
2 passages in order to retain cisplatin resistance.
4.6. MTT antiproliferative assays
SW480, A2780, A2780cis (1  104 cells/well) and A549
(5  103 cells/well) cells were seeded in 200 mL of their culture
medium per well in 96-well plates and incubated at 37 C under a
5% CO2 atmosphere for 24 h. Then, cells were treated with different
concentrations of the complexes under study and cisplatin as
positive control. After treatment, the compounds were removed
and cells were incubated with 100 mL of MTT (3-(4,5-
dimethyltiazol-2-yl)-2,5-diphenyltetrazoliumbromide) (500 mg/
mL). For photocytotoxicity experiments, A549 and CHO cells were
seeded for 24 h and incubated with the compounds for 1 h in the
dark followed by 1 h incubation under irradiation by placing the
Photoreactor EXPO-LED from Luzchem (Canada) fitted with LED Vis
lamps (blue lamps l ¼ 465 nm at a final light6 intensity of
12.6 J cm2) inside the CO2 incubator. Irradiated cell culture plates
subjected to light irradiation included control cells that were not
treated with complexes. Dark control samples were placed in the
dark 1 h and then kept in the dark 1 h. Drug-containing medium
was then removed by suction, cells washed with PBS and loaded
with complete cell medium for 24 h. After cell recovery period,
medium was removed and incubated with MTT solution. For pho-
tocleavage experiments, high concentrated DMF solutions of the
complexes under study were irradiated with blue light irradiation
(lirr ¼ 460 nm, 6.6 J cm2) for 20 min and 2 h. Then, the MTT Assay
was performed with these irradiated solutions after 24 h. After
incubationwith MTT, 100 ml of solubilizing solution (10% (w/v) SDS,
0.01 M HCl) was added to each well and the absorbance at 570 nm
was read in a microplate reader (Cytation 5 Cell Imaging Multi-
Mode Reader - Biotek Instruments, USA, and FLUOstar Omega).
Four replicates per dose were included and at least two indepen-
dent experiments were performed. IC50 values were calculated
from cell survival data using GraphPadPrism Software Inc. version
6.01 (USA).
4.7. Cellular uptake studies by ICP-MS
A549 cells were seeded in 6-well plates at a density of
5  105 cells per well and incubated at 37 C under a 5% CO29
atmosphere during 24 h. Then, cells were treated with 2 mM of
cisplatin and the studied Pt(II) complexes for 24 h. After that, cells
were washed twice with DPBS (Dulbecco's Phosphate Buffered
Saline) and harvested. Cells were resuspended in 1 mL of DPBS.
Cytoplasmic and nuclear fractions were obtained by a fragmenta-
tion protocol previously described [74]. Then, samples were diluted
with Milli-Q water to obtain 2% HNO3 solutions. Finally, solutions
were analyzed in an 8900 ICP-MS (Agilent Technologies). Data are
reported as the mean with the standard deviation of two inde-
pendent experiments performed by triplicate.
4.8. Photo-oxidation of NADH
The photocatalytic oxidation of NADH by complex 2 was
monitored by ultravioletevisible spectroscopy at 298 K in the dark
and under irradiation with blue light (465 nm, 18 J cm2). The
concentration of NADH was obtained using the extinction coeffi-
cient at 339 nm (6220 M1cm1) [75]. TON was defined as the
number of moles of NADH that a mol of complex 2 could convert in
30 min. TOF was calculated from the concentration of oxidized
NADH (calculated by the difference of concentration of NADH) after
30 min divided by the concentration of complex 2.
4.9. Confocal microscopy imaging of A549 cells
Briefly, A549 cells were seeded onto Ibidi m-slide 4 well at a
density of 3$104 cells/cm2 and allowed to attach to cell surface. Cells
were treated with tested compounds for 0.5 or 3 h at indicated
concentrations imaged under confocal microscopy using lexc ¼ 450
and lem ¼ 500e600 nm (Leica SP8 systems). Overlay images were
obtained with ImageJ software.
4.10. ROS generation assays
The ability of the metal complexes for ROS generation in
A549 cells was evaluated using dihydroethidium (DHE) as previ-
ously described [76,77]. Briefly, after A549 cells have been allowed
to attach the cell surface of 96-well plates (3$104 cells/well), com-
pounds (10 mM) were added following the described schedule for
phototoxicity. Then a staining solution (DHE, 10 mM) was loaded
into each well for 30 min. The staining was then removed, fluo-
rescence was measured in a FLUOstar Omega spectrophotometer
using lexc/lem ¼ 488/620 ± 10 nm (n ¼ 4 replicates) and data
analyzed with Microsoft Excel using unpaired t-test for statistical
significance. Alternatively, A549 cells seeded in 12-well plates fol-
lowed the same protocol and were imaged in an inverted fluores-
cence microscope (Zeiss Axio Observer 7) using the red channel.
4.11. Analysis of cell morphology
Cellular morphology analysis of A549 cells after 24 h treatment
with platinum complexes was performed using flow cytometry as
previously described [74,78]. Briefly, 2$105 cells/well were seeded
onto 12-well plates and incubated overnight at 37 C in a humidi-
fied incubator with 5% CO2. Compounds or cisplatin were diluted in
medium and added at indicated concentrations following the
described light-based treatment schedules (1 h incubation þ 1 h
irradiation with blue light) or for 24 h. Control cells were treated
with the vehicle (0.4% DMF). Cells were then collected by trypsi-
nization, washed with phosphate-buffered saline (PBS), and
analyzed by flow cytometry using forward-scattered light (FSCeH)
vs side-scattered light (SSCeH) to compare cell size and cell
complexity, respectively. Two independent experiments were
performed (n ¼ 2 replicates) and data analyzed using Flowing
Software 2.5.1 (104 events per sample).
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